pharmaceutical investing Alexion Announces Successful Phase 3 PREVENT Study of Soliris (Eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder
pharmaceutical investing Alexion Submits Application for Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria in the EU
pharmaceutical investing Positive Regulatory News from Two Pharmaceutical Companies Triggers Share Price Increases
CoTec and Battery Mineral Resources Enter Strategic Partnership to Unlock Additional Copper Production and Growth Opportunities at Punitaqui
Westport Rebrands as Aetherion Technologies, Focused on Accelerating Proven Solutions for Heavy-Duty Clean Transport
